A randomized, double blind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study.
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Acronyms RINOMAX
- 02 Apr 2018 Planned End Date changed from 1 Dec 2018 to 30 Jun 2020.
- 02 Apr 2018 Planned primary completion date changed from 1 Aug 2018 to 30 Sep 2019.
- 02 Aug 2016 New trial record